改良根治睾丸切除术治疗Ⅰ期睾丸精原细胞瘤
The modified radical orchiectomy of clinical stage-Ⅰ seminoma of the testis
目的 探讨改良睾丸根治性切除术治疗Ⅰ期精原细胞瘤安全性、有效性。 方法 回顾性分析2009年1月~2012年8月我院收治的28例Ⅰ期睾丸精原细胞瘤患者的临床资料,13例患者采用改良根治性睾丸切除术,15例患者采用传统经腹股沟根治性睾丸切除术。比较两组患者的年龄、手术时间、切口长度、术后疼痛评分、术后平均住院时间、并发症发生率、术后复发率。 结果 改良根治组和传统根治组两种手术方式手术均获得成功,在手术时间、并发症发生率及术后复发率方面两种手术方式无明显著异(P>0.05),但两组术后疼痛评分、切口长度、术后平均住院时间方面有显著差异(P<0.05),且改良根治组因切口比传统根治组小,更具美观效果。 结论 改良根治性睾丸切除治疗Ⅰ期精原细胞瘤是安全的,有效的,与经腹股沟根治性睾丸切除术相比,具有切口微创美观、术后疼痛轻、恢复快的特点。
Objective To study the effect of modified radical orchiectomy. Methods The clinical data of 28 cases of adult patients of clinical stage-Ⅰseminoma from January 2009 to August 2012 were retrospectively presented and analyzed. Among 28 cases of adult patients, 13 cases were cured by modified radical orchiectomy and 15 cases were cured by radical inguinal orchiectomy. The two ways of surgery were evaluated by the surgical duration, length of incision, hospitalization length after surgery, surgical complications, and neoplasm recurrence. Results The modified radical orchiectomy of 13 cases of adult patients of clinical stage-Ⅰseminoma was successfully rformed. There was not significant difference in modified radical orchiectomy and the radical inguinal orchiectomy with regard to the surgical duration, the surgical complication and the neoplasm recurrence, but the former was significantly lower than the latter in visual analogue scale(VAS), and significantly shorter in the length of incision and in hospitalization length Conclusions The modified radical orchiectomy of the clinical stage-Ⅰseminoma is advisable and safe. To contrast with traditional radical inguinal orchiectomy, this way of surgery has the characteristics of the smaller incision and themilder pain after the surgery.
[1] Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer
[J]. Eur Urol, 2005,48(6):885-894.
[2] Albers P, Albrecht W, Algaba F, et al. EAU guidelines on testicular cancer:2011 Update
[J]. Eur Urol, 2011,60(2):304-319.
[3] 陈志强,叶章群,庄乾元,等. 单切口双侧睾丸单纯切除术的手术入路
[J].临床泌尿外科杂志,2001,16(7):327-328.
[4] Singhera M, Lees K, Huddart R, et al. Minimizing toxicity in early-stage testicular?cancer treatment
[J].Expert Rev Anticancer Ther, 2012,12(2):185-193.
[5] Boujelbene N, Cosinschi A, Boujelbene N, et al. Pure seminoma: A review andupdate
[J]. Radiat Oncol, 2011,90(6):1-12.
[6] Cummins S, Yau T, Huddart R, et al. Surveillance in stageⅠseminoma patients: a long-term assessment
[J]. Eur Urol, 2010, 57(4): 673-678.
[7] Fedyanin M, Tryakin A, Kanagavel D, et al. Late relapses(>2years) in patients with stageⅠtesticular germ cell tumors: predictive factors and survival
[J]. Urol Oncol,
2011,31(4):499-504.
[8] 金昱,赵集中,杨镇洙.睾丸和附睾内淋巴管及其淋巴流向
[J].延边医学医学报,1989,12(4):225-227.
[9] 李晔雄.Ⅰ期精原细胞瘤的治疗进展
[J].中华放射肿瘤学杂志,2002,11(1):57-58.
/
〈 |
|
〉 |